摘要
目的:本研究旨在评估达格列净联合托拉塞米对慢性心力衰竭(CHF)患者的治疗效果及安全性。方法:选取2022年6月-2024年6月在瑞金市人民医院接受治疗的CHF患者106例,按随机数字表法分为研究组(n=53,予以格列净联合托拉塞米治疗)和对照组(n=53,予以托拉塞米治疗),治疗周期均为8周。比较两组临床疗效、左心室重构指标[左心室重塑指数(LVRI)和左心室质量指数(LVMI)、左心室射血分数(LVEF)和左心室舒张末期内径(LVEDD)]、NYHA心功能分级、6分钟步行试验(6MWT)及不良反应发生情况。结果:研究组的临床总有效率为92.45%,显著高于对照组的77.36%(P<0.05)。两组治疗后LVMI和LVEDD均降低,LVRI、LVEF均升高,且研究组优于对照组(P<0.05)。研究组治疗后NYHA心功能分级和6MWT距离优于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:达格列净联合托拉塞米能够显著改善CHF患者的心功能及左心室重构,且不增加不良反应风险。
Objective:This study aims to evaluate the efficacy and safety of Dapagliflozin combined with Torasemide in the treatment of patients with chronic heart failure(CHF).Method:A total of 106 CHF patients who were treated in People's Hospital of Ruijin City from June 2022 to June 2024 were selected and divided into the study group(n=53,treated with Dapagliflozin combined with Torasemide)and the control group(n=53,treated with Torasemide)by random number table method,the treatment duration were 8 weeks.The clinical efficacy,left ventricular remodeling indicators[left ventricular remodeling index(LVRI)and left ventricular mass index(LVMI),left ventricular ejection fraction(LVEF)and left ventricular end-diastolic diameter(LVEDD)],NYHA cardial function classification,6 minute walking test(6MWT),and the incidence of adverse reactions were compared between the two groups.Result:The total clinical effective rate of the study group was 92.45%,significantly higher than 77.36%of the control group(P<0.05).The LVMI and LVEDD decreased,LVRI and LVEF increased in both groups after treatment,the study group was superior to the control group(P<0.05).The NYHA cardiac function classification and 6MWT distance in the study group were better than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Dapagliflozin combined with Torasemide can significantly improve cardiac function and left ventricular remodeling in patients with CHF,without increasing the risk of adverse reactions.
作者
刘涛
杜海龙
谢坛林
LIU Tao;DU Hailong;XIE Tanlin(Department of Cardiovascular Medicine,People's Hospital of Ruijin City,Ruijin 342500,China;不详)
出处
《中国医学创新》
2025年第21期17-21,共5页
Medical Innovation of China
关键词
慢性心力衰竭
达格列净
托拉塞米
左心室重构
心功能
不良反应
Chronic heart failure
Dapagliflozin
Torasemide
Left ventricular remodeling
Cardiac function
Adverse reactions
作者简介
通信作者:刘涛。
